Community Health Systems Expands Partnership With Mark Cuban Cost Plus Drugs

Rhea-AI Summary

Community Health Systems (CYH) has announced an expansion of its partnership with Mark Cuban Cost Plus Drugs Company. This expansion enables CHS-affiliated hospitals to purchase more medications from the Cost Plus Drugs Marketplace, which is powered by GraphiteRx. The Marketplace offers hundreds of common medications at significantly lower costs, with a 15% markup on the actual cost of each drug.

Initially, CHS-affiliated hospitals will purchase twelve types of drugs, including antibiotics and medications for chemotherapy-related nausea, infections, glaucoma, acid reflux, and hyponatremia. This initiative is expected to save several hundred thousand dollars annually and may expand as more drugs are approved.

The partnership aims to address drug shortages and reduce pharmaceutical waste, with CHS becoming the first hospital organization to buy drugs from Cost Plus Drugs' new manufacturing plant in Dallas. Lynn Simon, M.D., and Alex Oshmyansky, M.D., PhD, emphasize the importance and potential of this collaboration for improving drug affordability and availability.

CHS-Affiliated Hospitals Begin to Purchase Medications from the Cost Plus Drugs Marketplace

FRANKLIN, Tenn.--(BUSINESS WIRE)-- Community Health Systems, Inc. (NYSE: CYH) (“CHS”) announced today that it is expanding its partnership with Mark Cuban Cost Plus Drugs Company, making more medications available – at significantly lower costs – to the Company’s affiliated hospitals.

This new phase of the partnership taps into the Cost Plus Drugs Marketplace, powered by GraphiteRx. The Marketplace offers hundreds of common medications at deeply discounted prices compared to many traditional pharmaceutical suppliers. Driven by its commitment to make drugs affordable and to offer transparent pricing, Cost Plus Drugs charges a 15% mark-up on the actual cost of each drug. In many cases, savings of hundreds, or even thousands, of dollars are available when purchasing drugs from the Cost Plus Drugs Marketplace.

CHS-affiliated hospitals will begin by purchasing twelve drugs from the Cost Plus Drugs Marketplace, including a variety of antibiotics, medication used to prevent nausea in patients undergoing chemotherapy, and pharmaceuticals administered for the treatment of certain infections, glaucoma, acid reflux, hyponatremia, and other conditions. Annual savings of several hundred thousand dollars are expected initially and may grow as more drugs are approved for purchase from the Cost Plus Drugs Marketplace.

Additionally, as CHS identifies new opportunities for savings on pharmaceuticals or a need for specific drugs that can help prevent or address drug shortages, Cost Plus Drugs will work to source those medications directly from their manufacturers.

“The benefits of this partnership are significant and include immediate savings on drugs frequently used in the hospital setting,” said Lynn Simon, M.D., CHS President of Healthcare Innovation and Chief Medical Officer. “Equally important, our collaboration is about strategically pursuing opportunities to address a wide variety of pharmaceutical-related issues affecting all U.S. hospitals. We have an opportunity to do things differently, and the Mark Cuban Cost Plus Drugs team is making very positive change possible.”

Earlier this year, CHS and Cost Plus Drugs announced that the two companies would work together to mitigate potential drug shortages, which are increasingly problematic for hospitals. CHS became the first hospital organization to purchase drugs from the new Cost Plus Drugs manufacturing plant in Dallas, Texas, which is equipped with aseptic robotic filling lines that produce sterile injectable medications. The first orders included norepinephrine and epinephrine. Epinephrine is on the Food and Drug Administration’s list of current drug shortages due to increased demand and manufacturing delays.

The partnership is also expected to reduce pharmaceutical waste and improve medication administration safety.

“A lot of healthcare organizations want a better, more innovative, and more cost-effective approach to drug purchasing,” said Alex Oshmyansky, M.D., PhD, Chief Executive Officer of Mark Cuban Cost Plus Drug Company. “Our partnership with CHS is proving that’s possible. We see unlimited potential to help U.S. hospitals, physicians, insurers, and most importantly, the patients, who need access to affordable medications.”

About Community Health Systems, Inc.

Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company's affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 40 distinct markets across 15 states. CHS subsidiaries own or lease 71 affiliated hospitals with approximately 12,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. More information about the Company can be found on its website at www.chs.net.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240627171569/en/

Media Contact:

Tomi Galin, Executive Vice President, Corporate Communications, Marketing and Public Affairs

(615) 628-6607

Investor Contacts:

Kevin Hammons, President and Chief Financial Officer

(615) 465-7000

Anton Hie, Vice President–Investor Relations

(615) 465-7012

Source: Community Health Systems, Inc.

FAQ

What is the latest news about CYH's partnership with Mark Cuban Cost Plus Drugs?

Community Health Systems (CYH) has expanded its partnership with Mark Cuban Cost Plus Drugs Company, allowing its affiliated hospitals to purchase more medications at significantly lower costs.

How will CYH-affiliated hospitals benefit from the expanded partnership with Cost Plus Drugs?

CYH-affiliated hospitals will benefit from lower medication costs and the initial purchase of twelve types of drugs, including antibiotics and medications for chemotherapy-related nausea.

What types of medications will CYH-affiliated hospitals initially purchase from Cost Plus Drugs?

They will initially purchase twelve types of drugs, including antibiotics, medications for chemotherapy-related nausea, infections, glaucoma, acid reflux, and hyponatremia.

How much savings is expected from CYH's expanded partnership with Cost Plus Drugs?

The partnership is expected to save several hundred thousand dollars annually, with potential for further savings as more drugs are approved.

What is the Cost Plus Drugs Marketplace, and how does it benefit CYH-affiliated hospitals?

The Cost Plus Drugs Marketplace, powered by GraphiteRx, offers hundreds of medications at deeply discounted prices, charging only a 15% markup on the actual cost, benefiting CYH-affiliated hospitals by reducing drug expenses.

Who commented on the significance of the CYH and Cost Plus Drugs partnership?

Lynn Simon, M.D., CHS President of Healthcare Innovation and Chief Medical Officer, and Alex Oshmyansky, M.D., PhD, CEO of Mark Cuban Cost Plus Drug Company, commented on the partnership's significance.

What are the broader goals of CYH's partnership with Mark Cuban Cost Plus Drugs?

The broader goals include addressing drug shortages, reducing pharmaceutical waste, and improving medication administration safety.

Where is the new Cost Plus Drugs manufacturing plant located?

The new Cost Plus Drugs manufacturing plant is located in Dallas, Texas.

What was the first type of drugs purchased by CYH from the new Cost Plus Drugs manufacturing plant?

The first orders included norepinephrine and epinephrine, with epinephrine being on the FDA's list of current drug shortages.

What is the primary focus of the Mark Cuban Cost Plus Drugs Company?

The primary focus is to make medications affordable and offer transparent pricing, with a 15% markup on the actual cost of each drug.